BARCELONA, Spain, October 6, 2026
Veeva Systems announced that its Veeva DQS (Data Quality System) has aggregated and cleaned clinical data for more than 1 million subjects across over 1,000 studies, highlighting the growing role of automated data management in modern clinical research. The company said the platform has generated more than 500,000 automated queries, helping sites and sponsors reduce the time, cost, and effort associated with manual data reconciliation. By accelerating the delivery of analysis-ready clinical data, Veeva DQS is designed to help clinical teams obtain trial insights more efficiently while supporting increasingly complex clinical development programs. The platform incorporates automated data workflows, risk-based quality processes, and artificial intelligence to help clinical teams manage growing volumes of data from multiple sources. Veeva said these capabilities are particularly relevant as sponsors and contract research organizations (CROs) adopt risk-based strategies recommended in regulatory guidance, including ICH E6(R3).
Veeva DQS Automates Clinical Data Reconciliation
A key focus of Veeva DQS is the automation of clinical data reconciliation, an activity that can require substantial manual effort as studies generate increasing amounts of information. According to Veeva, the platform has already processed data associated with more than 1 million study subjects, while its automated queries have helped save thousands of hours for clinical sites and sponsors. The system automates data workflows, classifies and visualizes critical information, and supports the orchestration of risk-based actions across the clinical ecosystem. These capabilities are intended to help clinical data teams identify important changes more quickly and reduce repetitive reconciliation activities. The company said sponsors and CROs are increasingly using Veeva DQS across studies of different sizes as clinical protocols become more complex and data sources continue to expand. The ability to prepare cleaner and more consistent data earlier in the clinical process can support more efficient downstream analysis and decision-making.
AI and RBQM Support Modern Clinical Trials
Veeva DQS also supports risk-based quality management (RBQM) through automated data exchange with Veeva CTMS. This connection is designed to help clinical operations teams identify important data changes, including protocol deviations, and respond to key risk indicators (KRIs). Clinical data teams can calculate, track, and take action on KRIs as part of a more integrated approach to clinical trial oversight. Another feature highlighted by Veeva is the use of data- and user-aware AI to accelerate classification of study data according to its purpose and criticality. The company said this capability can help generate items such as reports, listings, and test scripts while providing customized workflows based on individual user roles. These AI-enabled capabilities reflect the industry’s broader movement toward automated clinical data management, particularly as sponsors seek to improve data quality while managing increasingly sophisticated trial designs.
Advertisement
Veeva Expands Digital Clinical Development
The announcement also highlights Veeva’s broader efforts to improve the efficiency of clinical study development. The recently announced Veeva Study Builder Agent can configure Veeva EDC and Veeva DQS directly from a study protocol, with the aim of enabling faster and more consistent study builds. Together, these technologies are intended to connect study configuration, data collection, data quality, and risk-based review within a more integrated clinical development environment. Veeva serves more than 1,500 life sciences customers, ranging from large pharmaceutical companies to emerging biotechnology companies. As clinical trials generate increasing quantities of structured and unstructured data, automated platforms such as Veeva DQS could play an important role in helping clinical teams transform that information into high-quality, analysis-ready data. The company’s latest milestone demonstrates the growing adoption of digital and AI-enabled approaches to clinical data management and reflects the continued evolution of technology supporting pharmaceutical and biopharmaceutical research.
Source: Veeva Systems press release
